ClinicalTrials.gg
Not yet recruitingNCT07566520Updated May 5, 2026

Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt

An observational study in Osteoarthritis and Sarcopenia, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
224
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis by Assiut University — 8 open to participants now, 8 under way, none of them phase 3. Osteoarthritis · Assiut University.

Started
2026
with 3 others
Observational
5 of 13
3 open now
Registered
10th of 13
by date

Among the 13 studies in Osteoarthritis by Assiut University, this one is one of 4 that started in 2026, is one of 5 observational ones, and was the 10th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

8 of the 13 studies in Osteoarthritis by Assiut University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis by Assiut University, or all of them as a file.
02

Study summary

Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.

Read the detailed description

Chronic inflammation, joint pain, and reduced physical activity in OA patients create a vicious cycle that accelerates muscle mass loss and functional decline. While international data is robust, Egyptian epidemiological data remains limited. Recent studies in Egypt have identified a high risk of sarcopenia among older adults with fragility fractures and a prevalence of 17.7% in nursing home residents. However, targeted data on the OA population in Egypt is still lacking. Current management in Egyptian primary care centers primarily focuses on symptomatic relief of OA through analgesics and physical therapy. Sarcopenia often remains underdiagnosed because routine screening tools, such as the SARC-F questionnaire or Bioelectrical Impedance Analysis (BIA), are not yet integrated into standard family medicine protocols. This oversight leads to increased frailty and poorer surgical outcomes for patients requiring joint replacement. In the family medicine practice, identifying sarcopenia early is vital for holistic care. Understanding the local prevalence and risk factors-such as Vitamin D deficiency, sedentary behavior, and low protein intake-is essential to tailor interventions. This research aims to provide the evidentiary basis for incorporating sarcopenia screening into primary care OA management, ultimately improving patient mobility and quality of life

03

Conditions studied

  • Osteoarthritis
  • Sarcopenia
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.

Eligibility criteria

Inclusion Criteria:

  • Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.
  • Patients who are willing to participate and provide informed written consent.Exclusion Criteria:
  • Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.
  • Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.
  • Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).
  • Severe Comorbidities: end-stage renal or hepatic disease, advanced or cachexia.
  • Severe neurological disorders (e.g., Parkinson's disease, Stroke with paralysis) that directly affect muscle mass and mobility.
  • Prolonged use of systemic (which cause secondary sarcopenia)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
224 participants (estimated)
Patient registry
No

Groups and cohorts

  • Knee Osteoarthritis Patients

    Adults aged 40 years and older diagnosed with knee osteoarthritis based on the American College of Rheumatology (ACR) criteria attending the Assiut University Trauma Hospital.

06

What researchers measure

Primary outcomes

  1. Prevalence of sarcopenia in knee osteoarthritis patients

    Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.

    Time frame: at baseline

Secondary outcomes

  1. Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)

    Evaluation of nutritional status as a factor associated with sarcopenia. The MUST score is a five-step screening tool with a total score ranging from 0 (low risk) to 2 or more (high risk).

    Time frame: Baseline

  2. The Quality of Life Factor (EQ-5D Index)

    Assessment of the impact of sarcopenia and OA on quality of life. The 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression)

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Apr 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
May 5, 2026
StartEst.
May 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566520
Lead sponsor
Assiut University
Responsible party
Esraa Mostafa Hosny Ibrahim (Assistant Lecturer, Assiut University) — Principal investigator
First posted
May 5, 2026
Start date
May 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 5, 2026

Study contacts

Esraa M.H Ibrahim
Contact
esraa.m.hosny@aun.edu.eg
+201112969235

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion